Brief: Seikagaku says clinical trial for SI-449
Table: Seikagaku -2017/18 parent results
Table: Seikagaku -2017/18 group results
Table: Seikagaku -2017/18 group forecast
Brief: Seikagaku announces new drug application approval of hernicore® 1.25 units for intradiscal injection in Japan
Brief: Seikagaku initiates a phase III clinical trial (additional study) in the U.S. for SI-6603
Table: Seikagaku - 9-MTH group results
Brief: Ribomic signs collaborative research contract with SEIKAGAKU
Table: Seikagaku - 6-MTH group results
Table: Seikagaku -Q1 group results
Brief: Seikagaku initiates phase II study of SI-613 for treatment of knee osteoarthritis in U.S.
Table: Seikagaku -2016/17 parent results
Table: Seikagaku -2016/17 group results
Brief: Seikagaku initiates phase III study of SI-613
Table: Seikagaku -9-MTH group results
Brief: Seikagaku signs exclusive distribution agreement with Zimmer Biomet Holdings, Inc.
Table: Seikagaku -6-MTH group results
Brief: Seikagaku signs exclusive worldwide license agreement for treatment for lumbar disc herniation
Table: Seikagaku -Q1 group results